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In recent years, several newly identified T helper (TH) cell subsets, such as TH9, TH17,
and TH22 cells, and their respective cytokine products, IL-9, IL-17, and IL-22, have
been reported to play critical roles in the development of chronic inflammation in the
colorectum. Since chronic inflammation is a potent driving force for the development
of human colorectal cancer (CRC), the contributions of TH9/IL-9, TH17/IL-17, and
TH22/IL-22 in the pathogenesis of CRC have recently become an increasingly popular
area of scientific investigation. Extensive laboratory and clinical evidence suggests a
positive relationship between these new TH subsets and the growth and formation
of CRC, whereas, administration of IL-9, IL-17, and IL-22 signaling inhibitors can
significantly alter the formation of colorectal chronic inflammation or CRC lesions in animal
models, suggesting that blocking these cytokine signals might represent promising
immunotherapeutic strategies. This review summarizes recent findings and currently
available data for understanding the vital role and therapeutic significance of TH9/IL-9,
TH17/IL-17, and TH22/IL-22 in the development of colorectal tumorigenesis.
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INTRODUCTION
Colorectal cancer (CRC) is one of the leading causes of high cancer-associatedmortality worldwide.
According to the colorectal adenoma-carcinoma sequence theory, most CRCs develop from
pre-existing adenomatous lesions through a multistep process with the accumulation of genetic,
molecular and histological changes (1, 2). This process is significantly influenced by host
immunity (3–5). T-helper (TH) 1 immunity is believed to be the most important host immune
mechanism for keeping pre-neoplastic/neoplastic cells in check (6–8). To escape host immune
surveillance, however, pre-neoplastic adenoma cells can develop diverse strategies to suppress
antitumor immunity.
Studies in recent years have suggested that diverse TH subsets play a crucial role in the
processing and maintenance of chronic inflammation (9) and tumorigenesis (10), in which their
cytokine products play an essential role that modulates the development of the inflammatory
microenvironment provoked by tumorigenesis and affect tumor initiation/progression (3, 11, 12).
Therefore, there is great interest in studying the role of TH subsets and their cytokine products
in CRC initiation/progression. Indeed, many reports have observed notably altered immune cell
densities and cytokine profiles during CRC development (13–21), in which significantly increased
CD4 and CD8-positive T lymphocyte populations are observed (22–24), along with decreased
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expression levels of TH1 cytokines and increased expression
levels of TH2 cytokines in patients with CRC (7, 8, 25, 26).
Recent studies have also revealed that altered cytokine profiles
are correlated with disease stage and prognosis in patients with
CRC (25, 27–29). Furthermore, both in vivo and in vitro studies
have demonstrated that blocking cytokine signaling, as seen in
interleukin (IL)-6 and IL-17 studies, significantly suppresses cell
growth, proliferation, progression, and metastasis in CRC (21,
30). Therefore, ample evidence suggests that cytokines are not
only key contributors to the pathogenesis of CRC (18, 20, 31–34)
but also potential immunotherapeutic targets for the treatment
and prevention of CRC (35, 36).
Recently, several newly identified TH subsets, for example,
TH9, TH17, and TH22, have been reported to be associated with
the development of chronic inflammation and carcinogenesis.
The cytokine products of these subsets, IL-9, IL-17, and
IL-22, respectively, are potent proinflammatory mediators
and greatly contribute to the initiation and maintenance
of colorectal inflammatory disorders (9, 37–39). Emerging
evidence suggests that these cytokines are also involved in the
development and progression of CRC, as administration of
cytokine inhibitors significantly suppressed the development of
colorectal inflammation and subsequent CRC occurrence
in mice. Therefore, an improved understanding of the
immunopathogenesis of TH subsets and their cytokine products
will be helpful for designing novel translational/targeted
approaches to CRC (40).
In view of the importance and increasing data about TH9,
TH17, and TH22 cells and their associated cytokines in the
initiation and development of CRC, here, we review recent
findings, with an emphasis on the function of TH9/IL-9, TH17/IL-
17, and TH22/IL-22 in the pathogenesis of CRCs, and discuss
the therapeutic significance of these main cytokines in the
prophylaxis of CRC.
TUMOR-INFILTRATING LYMPHOCYTES
(TILS) AND CHROMOSOMAL INSTABILITY
IN PATIENTS WITH CRC
TILs in colorectal adenoma/CRC have been intensively studied.
The results suggest that significantly increased densities of TILs
are observed in both the tumor stroma and adenoma/CRC
epithelium (41, 42), and have clinical significance in predicting
prognosis and chemotherapeutic outcomes in patients with CRC
(43–46). Phenotypic analysis revealed that these TILs are mostly
CD4-positive and CD8-positive cells. CD4-positive TILs are
predominantly TH cells localized within the tumor stroma, and
Abbreviations: CAC, colitis associated cancer; CCR, CC chemokine receptor;
CD, Crohn’s disease; CRC, colorectal cancer; DMH, 1,2-dimethylhydrazine; DMP,
the DOTAP modified mPEG-PCL micelles; DSS, dextran sulfate sodium; IBD,
inflammatory bowel disease; IFN-γ, interferon γ; IL, interleukin; IL-17RA, IL-17
type A receptor; IL-22BP, IL-22 binding protein; MMP, matrix metalloproteinase;
MMR, mismatch repair; MSI, microsatellite instable; NF-κB, nuclear factor kappa
B; p-Akt, phosphorylated-protein kinase B; TGF-β, transforming growth factor β;
TH, T helper; TIL, tumor-infiltrating lymphocyte; TNF-α, tumor necrosis factor
α; Treg, regulatory T cell; UC, ulcerative colitis; VEGF, vascular endothelial
growth factor.
CD8-positive TILs are cytotoxic T lymphocytes (CTLs) that
infiltrate both the tumor stroma and adenoma/CRC epithelium
(23, 47–50). In addition, clinical molecular analysis revealed that
∼85% of CRCs may present with chromosomal instability, while
15% display DNA mismatch repair (MMR) (51, 52). Therefore,
another issue worthy of consideration is the influence of DNA
microsatellite instability (MSI) on the presentation pattern of
lymphocyte infiltration in CRC. Indeed, Boissière-Michot et al.
(53) have reported that CRCs with MSI exhibited increased
densities of CD3-positive, CD8-positive, CD45RO-positive, and
T-bet-positive TILs compared with those of microsatellite stable
(MSS) CRCs, whereas, the density of FoxP3-positive regulatory
T cells (Tregs) was not significantly different between the two
groups (53). Lee et al. examined TILs in CRCs with MSI and
found that CD8-positive TILs, but not CD4-positive TILs, were
significantly increased in both tumor cell niches and the tumor
stroma in CRCs with MSI (54). Similarly, Matsutani et al.
(23) recently showed that the density of CD8-positive TILs
is associated with MMR status in CRC and intratumor CD8-
positive TILs in the invading margins in randomly selected
fields, and tends to be higher in MMR-deficient patients than
in MMR-proficient patients (23). More recently, several studies
have shown that chromosomal instability patterns significantly
influence the infiltration of CD8-positive lymphocytes, survival,
and therapeutic response in patients with CRC (55–57).
Collectively, these results demonstrate that chromosomal
instability status in patients with CRCmay significantly influence
TIL infiltration.
THE ROLE OF TH9/IL-9, TH17/IL-17, AND
TH22/IL-22 IN THE DEVELOPMENT OF
CRC
TH9/IL-9
TH9, a novel subset of TH cells that primarily produce IL-9 (58),
has recently been shown to be involved in the pathogenesis of
inflammatory bowel disease (IBD) (59, 60). The production of
IL-9 by TH cells is stimulated by IL-4, IL-21, and transforming
growth factor (TGF)-β and inhibited by interferon (IFN)-γ (61).
Transcriptional studies have revealed that the production of IL-
9 by TH9 cells is regulated by PU.1 (an ETS family transcription
factor) (62), and there is ample evidence to suggest that the TH9
cytokine IL-9 could be a strong proinflammatory factor in the
induction of experimental colitis (38, 63–65). An animal study
showed that TH9 cells labeled with PU.1 were markedly increased
in the inflamed mucosa (lamina propria) of dextran sulfate
sodium (DSS)-induced colitis mice (66). In human ulcerative
colitis (UC) specimens, we found that increased populations
of PU.1-positive TH9 cells were predominantly located in the
lamina propria, whereas, intraepithelial TH9 cells were present
at very low densities and were only occasionally observed (66).
However, it is worth noting that PU.1 is not a lineage-specific
transcription factor for IL-9 induction in TH9 cells, as it can
also be expressed in other subsets under certain circumstances.
For example, it has been reported that PU.1 is expressed in
B cells (67). In addition to PU.1, ETV5, another ETS family
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member, is an essential transcriptional factor for TH9 cells,
as deficiency of both ETV5 and PU.1 in T cells results in
markedly reduced induction of IL-9 (68). Therefore, a range
of transcription factors might be involved in the differentiation
of TH9 cells (69). Furthermore, a number of clinical studies
have revealed that serum levels of IL-9 in patients with UC
or Crohn’s disease (CD) are higher than those in controls,
and increased levels of IL-9 are significantly associated with
inflammatory activity in the bowel in patients with UC or CD
(37, 70, 71). Tian et al. showed that the involvement of IL-
9 in the pathogenesis of UC occurs through activation of the
Stat3/SOCS3 signaling pathway (72). These data support the
notion that the activation of the TH9 subset and its cytokine
product, IL-9, participates in the regulation of inflammatory
processes in the bowel. Since chronic inflammation, as seen in
IBD,may predispose patients to CRC development, the role of the
proinflammatory cytokine IL-9 in the development of CRC has
begun to attract increasing attention. Indeed, published studies
have explored the role of IL-9 in different types of cancers, and
both antitumor and protumor effects have been reported (73–
75). Rivera Vargas et al. demonstrated that autophagy controls
IL-9 secretion by TH9 cells and that selective autophagy targets
PU.1 for degradation in CD4T cells, resulting in the negative
regulation of TH9 homeostasis and antitumor immunity (73,
76). Two clinical studies performed in southern China reported
that expression levels of IL-9, in both the plasma and CRC
tissues, are lower in patients with CRC compared to levels
in healthy controls and are significantly associated with TNM
staging. CRC patients with advanced stages have reduced levels
of IL-9 compared to those with early stages (77, 78). Liu et al.
demonstrated that IL-9 induces the conversion of Tregs to TH9
cells, subsequently inhibiting tumor growth in the CT26 colon
cell line (79). Wang et al. reported a similar finding in Chinese
patients with CRC. They found that the expression levels of IL-
9 protein and messenger RNA were lower than those in the
controls and correlated with TNM staging, Dukes staging, lymph
nodemetastasis, and good prognosis. In vivo, IL-9 overexpression
significantly inhibited tumor growth and resulted in a longer
survival time in a mouse subcutaneous allograft model (80).
Moreover, an ectopically expressed membrane-bound form of
IL-9 induces an immunostimulatory effect that suppresses the
growth of CT26 colon cancer cells (81). These studies seem
to suggest that TH9 cells have an antitumor effect that largely
depends on their ability to secrete IL-9 and may influence tumor
growth by enhancing immune responses (73).
In contrast to the above findings, other studies have described
a protumor effect of IL-9. We have more recently demonstrated
that a population of IL-9-positive cells and protein expression
levels of IL-9 are greatly increased in mouse colitis-associated
cancer (CAC) tissues, compared to those of control mouse
tissues (82). Tian et al. examined the expression levels of IL-
9 in 12 pairs of CAC tissues and adjacent non-tumor tissues
by immunohistochemistry, and found that the expression of IL-
9 in CAC tissues was markedly higher than that in adjacent
tissues (83). In vivo, this study showed that IL-9 overexpression
in RKO and Caco-2 colon cancer cell lines results in an increasing
proliferation rate that occurs through upregulating expression of
c-Myc and cyclin D1 (83). Furthermore, a study from Poland
demonstrated that serum levels of IL-9 in 104 CRC patients
were significantly higher than those in controls (84), in contrast
to reports from southern China (77, 78). Hoelzinger et al.
recently used IL-9-deficient mice to investigate the effects of IL-
9 in multiple models of breast and colon cancer development.
These authors found that eliminating endogenous IL-9 enabled
sensitization of host T cells to tumors, leading to early rejection
without the requirement for vaccines or immunomodulatory
therapies. Notably, IL-9-deficient mice acquired immunologic
memory, which actively protected them from residual disease and
tumor re-challenge, an effect that is linked to the activation of
CD8-positive T cells (74).
Collectively, the current literature has revealed that TH9/IL-9
exhibit both antitumor and protumor effects (Figure 1). These
controversial results could be due to the distinct experimental
models, techniques and tumorigenesis conditions used in
different studies. Moreover, contradictory data may also stem
from differential effects of IL-9 on immune (antitumor) vs.
cancer (protumor) cells. Therefore, the effect of TH9/IL-9 in the
development of CRC is still an issue of debate, and much work
remains to be done.
TH17/IL-17
The IL-17-expressing TH cell subset (known as TH17 cells) is
another TH cell subset related to colorectal inflammation and
tumorigenesis (39). Studies suggest that the differentiation of
TH17 cells is stimulated by a set of upstream cytokines, including
IL-1β, IL-6, IL-21, IL-23, and TGF-β, and the main cytokine
products of this cell type are IL-17A and IL-17F (39). It should be
mentioned that the intestine is a site of origin for TH17 cells, and
whether they function as non-pathogenic TH17 cells promoting
homeostasis or pathogenic TH17 cells involved in infection and
autoimmunity is dependent on the upstream stimulator. TGF-
β stimulation skews the differentiation of TH17 cells to a non-
pathogenic phenotype that promotes homeostasis, and IL-23
accelerates the differentiation of TH17 cells toward a pathogenic
phenotype that is involved infection and autoimmunity. Some
previous studies have shown an antitumor effect of IL-17. For
instance, Kryczek et al. reported that subcutaneous injection
of the MC38 murine colon cancer cell line into IL-17-deficient
mice resulted in faster growth and increased lung metastasis
foci compared to that of wildtype control mice (85). Previous
studies have demonstrated that the antitumor effect of IL-17
in various cancer types is related to enhanced recruitment and
activity of lymphocytes, natural killer (NK) cells, and DCs into
the tumor site and production of the antitumor cytokine IFN-γ
(86–89). Lin et al. showed that CRC patients with higher IL-
17 levels tend to have a better prognosis than those with lower
IL-17 levels (90). However, the majority of published studies
suggest that TH17/IL-17 has profound effects on triggering and
amplifying the inflammatory process and tumorigenesis in the
colorectum (21, 91, 92). Considerable evidence suggests that
increased expression profiles of the TH17 cytokine product, IL-
17A, are associated with the production of the proangiogenic
factor vascular endothelial growth factor (VEGF) and poor
prognosis in patients with CRC (93). The profile of circulating
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FIGURE 1 | Schematic representation of TH9/IL-9’s role in CRC pathogenesis. Current data have yielded controversial results; both pro-tumor and anti-tumor effect
have been reported.
and intra-tumoral TH17 cells in patients with colon cancer, with
respect to tumor staging, was analyzed. The results revealed
that the percentage of TH17 cells in both the peripheral blood
and cancer tissues, assessed by multicolor flow cytometry, was
significantly increased in cancer patients compared to that of
healthy controls or adjacent non-tumor tissues, respectively. In
addition, the percentage of TH17 cells in both the peripheral
blood and cancer tissues was associated with disease stage, and
it was higher in patients with advanced stages than in those with
early stages (94). Furthermore, functional studies identified that
the type A receptor (IL-17RA) is a critical mediator of IL-17 in
promoting colorectal tumorigenesis (95). We have, for the first
time, examined IL-17A dynamics along the human colorectal
adenoma-carcinoma spectrum (31) and have found that the
expression of IL-17A, at both the mRNA and protein levels, was
significantly increased in the adenoma stage and persisted to the
CRC stage. Since the differentiation of TH17 cells is stimulated
by a set of cytokines, IL-1β and IL-6, which are important for
early stages, and IL-23, which is important for late stages of
development and the expansion of TH17 cells, we examined these
stimulating factors. The data showed that TH17 differentiation-
stimulating factors IL-1β, IL-6, and IL-23, but not TGF-β,
were significantly increased in a similar expression pattern
as IL-17 along the colorectal adenoma-carcinoma sequence,
suggesting activated TH17 differentiation and elevated IL-17
production throughout this sequence. Interestingly, we found
that increased IL-17 expression levels was associated with an
increased dysplasia grading score in adenomas, which is one
of the most important histological parameters in assessing the
neoplastic progression of an adenoma toward a CRC. Analysis
of IL-17A gene variants revealed that heterozygous rs10484879
was associated with increased disease risk, while the rs3748067
genotype was associated with a reduced risk of CRC (96). Samiei
et al. revealed that the IL-17A197AA genotype was significantly
associated with an increased CRC risk in Malaysian patients,
compared with those with the GG and AG genotypes (97).
These data suggest that IL-17A increases susceptibility to CRC.
More recently, the contribution of IL-17 to chemotherapeutic
agent resistance in CRC has been investigated. Cisplatin-based
anticancer therapy is an important chemotherapeutic strategy for
the treatment of CRC. Sharp et al. reported that elevated systemic
levels of the TH17 cytokines, IL-17F and IL-23, were associated
with stage IV colon cancer (98). Furthermore, the effect of IL-17
on the induction of chemoresistance in CRC is mediated through
targeting phosphorylated protein kinase B (p-Akt), the apoptosis
regulators Bax and Bcl-2 and the serine/threonine-protein kinase
mTOR (99).
Despite general advances in diagnosis and treatment, the
long-term survival of CRC remains low, except when early
curative surgery is performed. The prognostic significance of
TH17/IL-17 in human CRC has been evaluated. Le Gouvello et al.
have shown that increased expression of IL-17 in CRC tumor
tissues is associated with proficient MMR status, indicating
poor prognosis in patients with CRC (100). Other studies have
also confirmed that increased levels of IL-17 are associated
with aggressive features and poor prognosis in CRC (93, 101).
Moreover, a clinical study revealed that CRC patients with high
expression of the TH17 cluster and a high density of IL-17-
positive cells in situmay have a shorter disease-free survival time
and early relapse after primary CRC tumor surgical resection
(24). Since systemic metastasis has often already occurred at
diagnosis, approximately half of CRC patients ultimately die
due to relapse and metastasis after resection of primary tumors
(102). Therefore, recent studies have explored the influence of
TH17/IL-17 on CRC metastasis. The promoting effect of IL-
17 on colorectal tumorigenesis has been reported in mouse
CRC models (103). The data showed that the development of
CRC is facilitated via the activation of TH17 cells, whereas,
blocking IL-17A signaling significantly suppressed hyperplastic
and neoplastic lesion formation (103), suggesting that activation
of TH17/IL-17 plays an important role in the formation of
premalignant lesions and the establishment of CRC lesions.
Thus, targeting TH17/IL-17 signaling may represent a promising
approach for future CRC immunotherapy (104).
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In addition to IL-17A, IL-17F has been shown to be another
potential factor involved in the development of CRC. Tong et al.
have shown a protective effect of IL-17F in the development of
CRC. They found decreased tumor growth of IL-17F-transfected
HCT116 cells compared to that of mock transfectants when
transplanted into nude mice. However, increased colonic tumor
numbers and tumor areas were detected in IL-17F-deficient
mice compared to those of wildtype mice after colon cancer
induction (105). Furthermore, Nemati et al. found that the IL-
17F T7488 allele is associated with a decreased risk of CRC and
tumor progression, whereas, the AG genotype of the IL-17A
G197A SNP is associated with an increased risk of CRC (106).
However, Chae and Bothwell reported that IL-17F deficiency
significantly inhibits spontaneous intestinal tumorigenesis in the
small intestine of Apc(Min/+) mice, probably through decreased
IL-1β, Cox-2, and IL-17 receptor C (IL-17RC) expression and
decreased infiltration of immune cells in the lamina propria
(107). The role of IL-22 in the pathogenesis of CRC is also
somewhat controversial (see TH22/IL-22 section). In addition,
TH17 cells under certain circumstances can coproduce IL-
9, IFN-γ, or IL-10. The function of these cytokines in the
development of CRC might be significantly different. Finally,
some TH17 cytokines can be made by many TH subsets, and
TH17 differentiation-stimulating factors may also regulate other
TH subsets under certain conditions. This makes the cytokine
network in human tumors very complex.
In summary, current evidence has shown that IL-17 promotes
metastasis in CRC. Possible mechanisms by which this occurs
include the following: (1) IL-17 stimulates the activation of
metastasis-related genes, such as tumor necrosis factor-α (TNF-
α), nuclear factor kappa B (NF-κB), CC chemokine receptor
6 (CCR6), matrix metalloproteinase (MMP)-2, MMP-7, MMP-
9, and MMP-13 (108–111). (2) IL-17 potentially enhances
angiogenesis by increasing the production of VEGF (93, 104).
Further studies revealed that IL-17 does not directly stimulate
the growth of vascular endothelial cells but strongly induces
the migration and cord formation of endothelial cells (92, 112).
(3) IL-17 is capable of remodeling the CRC stroma (113). (4)
IL-17 promotes the production of myeloid-derived suppressor
cells that create a favorable milieu for CRC development and
progression (114–117). Therefore, the involvement of TH17/IL-
17 in the pathogenesis of CRC occurs through a mixed
pathway (Figure 2).
TH22/IL-22
TH22 cells compose another novel T cell subset. RORγt acts
as a positive transcription factor and T-bet acts as a negative
transcription factor for TH22 cell differentiation (118). In
addition, AhR has also been considered a transcription factor
for IL-22 produced by TH22 cells (119). TH22 cells produce
cytokines, such as IL-22, IL-26, and IL-33. Although it is not
clear whether TH22 cells are a separate subset or derived from
TH17 cells, given that there is still debate about whether IL-22
is also a TH17 cytokine, many observations obtained over the
past few years have indicated that numerous factors, including
IL-1β, IL-6, IL-21, and IL-23, may stimulate the production of
IL-22 in activated TH22 cells (118, 119). The role of IL-22 in
modulating the progression of inflammation, as seen in IBD,
has been primarily studied (120, 121). However, these results are
somewhat controversial. One study reported that UC patients
exhibited significantly reduced numbers of IL-22-positive cells
in actively inflamed tissues, compared with the numbers in both
non-inflamed tissues and normal tissues from healthy controls
(9). Another study conducted in patients with CD reported
that IL-22 protects the intestinal barrier by enhancing intestinal
epithelial cell migration in CD (122), which was supported
by the findings that anti-TNF-α therapy in patients with CD
results in increased IL-22 production by CD4-positive T cells
and enhanced repair of damaged mucosa (123). Sugimoto et al.
reported that IL-22 gene delivery elicited rapid attenuation
of local intestinal inflammation by enhancing Stat3 activation
within colonic epithelial cells in mice (124). However, other
studies have shown the opposite relationship between TH22/IL-
22 and chronic inflammation in the colorectum. Analysis of
IL-22 levels and circulating TH22 cells in UC showed that
UC patients had higher levels of IL-22 and TH22 cells than
those of healthy controls, and both features were associated
with disease severity (125, 126). In addition, IL-22 antibody
administration significantly reduced colorectal inflammation
in DSS-induced colitis mice compared with that of control
mice (127). Therefore, current data from most studies suggest
that TH22/IL-22 might participate in the development and
modulation of colorectal inflammation.
Regarding the role of TH22/IL-22 in cancers, evidence from
early studies revealed that IL-22 promotes the growth of tumor
cells in many types of cancers, including lung adenocarcinoma
and hepatocellular carcinoma (128, 129). In patients with gastric
cancer, dysregulation of circulating TH22 cell frequency and IL-
22 expression levels have been demonstrated, and were associated
with advanced tumor features and patient survival (130, 131).
Regarding the role of TH22/IL-22 in CRC, in vitro studies have
shown that IL-22 enhances nitric oxide synthase expression in
colon cancer cells, significantly contributing to conversion to
nitrites, which are associated with colonic inflammation and
carcinogenesis (132). Subsequent studies have shown that IL-22
has a direct proliferative effect on colonic epithelial cells (133).
Sun et al. revealed that coculture of single cells, isolated from
colon cancer tissues with recombinant IL-22 for 24 h, resulted
in a significantly increased proliferation rate, which could be
blocked by an anti-IL-22 antibody (134). Furthermore, IL-22
potentially stimulates intestinal epithelial cells to secrete IL-10,
a main contributor to the formation of an immunosuppressive
milieu in CRC (135). IL-22 has also consistently been shown
to be protumor in CRC animal models. The results obtained
from both in vivo and in vitro models illustrated that IL-22 is
associated with CRC progression through activating the Stat3
pathway (133, 134, 136, 137). Various studies in recent years
have attempted to clarify the promoting effect of IL-22 in the
pathogenesis of CRC. The results showed that BALB/c nude
mice transplanted subcutaneously with RKO colon cancer cells
tended to have faster tumor growth after intraperitoneal injection
of IL-22 every other day, compared to that of control mice
(136). Recently, Wang et al. revealed that IL-22 is associated
with the development of dysplasia in a murine model of CAC
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FIGURE 2 | Schematic representation of TH17/IL-17’s role in CRC pathogenesis. Most current studies have demonstrated that TH17/IL-17 exhibits a pro-tumor effect
on the development of CRC through a mixture of mechanisms.
(138). By using IL-22BP-deficient mice, Huber et al. showed that
the soluble receptor of IL-22, IL-22 binding protein (IL-22BP),
has a crucial role in controlling tumorigenesis and epithelial
cell proliferation in the mouse colon (133). In support of the
hypothesis that TH22 is involved in the development of CRC,
Doulabi et al. reported that increased populations of intratumoral
TH17, TH22, and CD4-positive T cells, coproducing IL-17/IL-
22 in patients with colon cancer, were observed in tumor
tissues (94). This result is in contrast with the results of a
previous study that reported markedly reduced percentages of
TH22 cells and IL-22 levels in CRC patients, compared with
those of healthy controls that were negatively associated with
the pathological stages of CRC (139). Another clinical study
demonstrated that the percentage of TH22 cells in the CD4-
positive T cell subset was significantly higher in CRC tissues,
compared to that of para-tumor tissues, as determined by flow
cytometry in patients with CRC (136). In addition, IL-22 genetic
polymorphisms have been shown to be a risk factor for colon
cancer (140), and elevated serum IL-22 levels correlate with
chemoresistance in patients with CRC (141). Furthermore, both
IL-22 and its functional transmembrane receptor (IL-22R1) have
been found to be significantly expressed in CRC epithelial and
tumor stromal cells (142). Taken together with the above findings,
most current data suggest a promoting effect of TH22/IL-22 on
the development of CRC (see Figure 3), making it an attractive
target for anticancer therapy.
Potential Therapeutic Significance of
TH9/IL-9, TH17/IL-17, and TH22/IL-22 in
CRC
Because of the current lack of effective immunotherapies for
the treatment of CRC, the search for novel immunotherapeutic
targets has become critically important (36, 143). Strong evidence
now suggests that chronic inflammation is a potent driving
force for tumor development, in which diverse TH cells and
their cytokine products play essential roles (144, 145). It is
therefore hypothesized that TH cells and their cytokine network
may represent potential therapeutic targets for the treatment of
human cancer (14, 146–151). Immunotherapy against various
cancer types, including CRC, has been well-reviewed (146,
152). These outstanding reviews have indicated that current
immunotherapy strategies, including anti-cytokine antibodies,
immune adjuvants, and vaccines, immune checkpoint inhibitors
and immune cell-based therapies, can potentially enhance host
antitumor immune function and prolong patient survival time in
human cancers (152, 153).
As the above findings indicated that TH9 and its cytokine
product IL-9 are associated with the development of chronic
inflammation in the colorectum, additional studies further
analyzed the therapeutic effect of blocking IL-9 signaling in
a colitis mouse model (66). We were able to show that
blocking IL-9 signaling by intraperitoneal administration of
IL-9 antibody rapidly ameliorates colorectal inflammation in
DSS-induced colitis mice (66). However, the role of TH9/IL-
9 in the development of CRC remains unclear. To the
best of our knowledge, studies examining the therapeutic
effect of blocking IL-9 signaling in the development of CRC
remains to be investigated. Furthermore, several studies have
looked at the therapeutic effect of blocking IL-17A in the
treatment and prevention of CRC (92, 110–112). Numasaki
et al. have shown that IL-17 promotes tumor cell growth in
vivo by enhancing angiogenesis in mice with MCA205/IL-17
tumors, while angiogenic activity was markedly suppressed by
a neutralizing IL-17 monoclonal antibody (112). We previously
demonstrated that administration of an IL-17A antibody strongly
suppresses the development of DSS/DMH-induced CRC in
mice (20). These findings have highlighted a key role of IL-
17 in CRC development. Currently, secukinumab, ixekizumab,
and brodalumab, which are biological agents that target IL-17
signaling, are being studied and have successfully passed phase
III clinical trials for rheumatoid arthritis and psoriatic arthritis.
These antibodies may represent new options for potential CRC
treatments; therefore, it would be interesting to evaluate the
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FIGURE 3 | Schematic representation of TH22/IL-22’s role in CRC pathogenesis. Evidence obtained from most studies has suggested that TH22/IL-22 promotes the
development of CRC through diverse pathways.
therapeutic effect of these antibodies alone or combined with
chemotherapy in treating relapsed or metastatic CRCs (104).
Since the TH22-related cytokine IL-22 has been reported to
promote tumorigenesis in distinct cancer entities, including lung,
ovarian, breast, gastric, pancreatic, and colon cancers, the IL-22-
IL-22R1 pathway has become an attractive target for anticancer
therapy (154–156). An examination of the role of IL-22 in
lung adenocarcinoma has shown that IL-22 in K-ras-driven
lung cancer mediates tumor proliferation and remodeling of
the tumor microenvironment in a mouse model (129). Since
a previous study demonstrated that IL-22 has a crucial role
in controlling tumorigenesis and epithelial cell proliferation in
the colon (133), IL-22 may represent an attractive therapeutic
target. Sun et al. examined the effect of IL-22 on the proliferation
of single cells from colon cancer tissues by coculture with or
without recombinant IL-22 for 24 h. The results showed that
recombinant IL-22 stimulates colon cell proliferation, while anti-
IL-22 blocks this effect (134). Another study tested the efficacy of
a novel IL-22BP-based colon cancer gene therapy strategy (157).
By delivering the IL-22BP gene with a newly developed non-
viral gene vector, DOTAP-modified mPEG-PCL micelles (DMP),
the inhibitory efficacy of the DMP/IL-22BP complex on mouse
colon cancer was examined via intraperitoneal administration.
These results showed that the DMP/IL-22BP complex blocked
IL-22 signaling and exhibited a significant inhibitory effect on
cancer cell growth both in vitro and in vivo. These anticancer
mechanisms may be related to induction of apoptosis, enhanced
infiltration of lymphocytes in tumor tissues and inhibition of
angiogenesis. The results suggest that blocking IL-22 signaling
may represent a promising strategy for CRC cancer gene therapy
(157). Administration of a specific antibody is one of the simplest
and most efficient methods to block cytokine signaling, and
one study demonstrated that antibody-based targeted delivery
against IL-22 in DSS-induced colitis mice resulted in more
rapid recovery from clinical symptoms and improved colon
morphology compared to controls (127). Currently, the delivery
of IL-22 antibodies in a CRC animal model has not been tested,
and evaluation of therapeutic efficacy remains unknown.
CONCLUDING REMARKS
Current findings suggest a pivotal role of the TH subsets,
TH17 and TH22, in the pathogenesis of CRC. In this context,
their cytokine products have been identified as key contributors
in CRC tumorigenesis through several pathways, such as
stimulating proliferation, enhancing angiogenesis, recruiting
immune suppressor cells, and remodeling tumor stroma.
Therefore, strategies aimed at suppressing these cytokine signals
as a new immunotherapeutic option for the treatment and
prevention of CRC are of key interest. Regarding the role of
TH9 and its cytokine product IL-9 in the pathogenesis of CRC,
it is rather diverse as it can have a protumor function as well as
antitumor characteristics. Therefore, the contribution of TH9/IL-
9 in CRC development remains an issue of debate. It is hoped that
further studies will eventually elucidate the precise mechanisms
and molecular characterization of signaling pathways involved in
TH subset cytokine actions in CRC, which will in turn help to
improve immunotherapeutic approaches.
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